ClinicalTrials.gg
RecruitingNCT07355413Updated Oct 2, 2026

Frailty, Geriatric Syndromes and Care Pathways of Older Adults Living With HIV in West Africa

An observational study in Older Adults, sponsored by ANRS, Emerging Infectious Diseases. Recruiting at 6 sites in 3 countries. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by ANRS, Emerging Infectious Diseases · Observational

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Oct 2, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
600
Ages
60 Years and older
Sex
All
01

Study summary

With currently available antiretroviral therapy, people living with HIV (PLWHIV) are living longer. This exposure to HIV and combination antiretroviral therapy may accelerate the aging of this population, thus increasing the prevalence of premature frailty.

There are few data on the prevalence of frailty and geriatric syndromes among older people living with HIV (OpHIV) in sub-Saharan Africa (SSA) and the screening and diagnostic tools to identify them.

The initiation contract financed by the ANRS-MIE in 2021 whose objective was to 1) carry out an inventory and evaluate the feasibility of a project for monitoring OpHIV in Burkina-Faso in Côte d'Ivoire and Togo and 2) to select the collection tools adapted to the description of geriatric syndromes in these elderly people has allowed to highlight the following (i) The collection of data on geriatric conditions and syndromes is almost non-existent in the daily care and management practice (ii) there is a significant proportion (10,6%) of PLWHIV aged 60 years and over in the active files of the PLWHIV care centers that participated in the survey (iii) Adapted screening tools have been selected and will allow documentation of the above-mentioned syndromes. This research project, which follows on from this initiation contract, will therefore make it possible to obtain data from the geriatric evaluation, to identify the specificities of PLWHIV by comparing them to a population not infected with HIV and to propose geriatric management adapted to PLWHIV. Its innovative nature also lies in its mixed approach combining quantitative and qualitative methods, which will make it possible to document the needs and resources for the care of PLWHIV in a global and holistic manner.

600 participants, aged 60 years and over (300 living with HIV and 300 not living with HIV), in three West African countries (Burkina Faso, Côte d'Ivoire, Togo) will be included in this study whose primary objective is to compare the prevalence of frailty among people aged 60 years and over (PA60) between HIV-infected and non-HIV-infected; the secondary objective is to estimate the prevalence of frailty among PA60 according to HIV status. A population-based matching will be performed on sex and age class (threshold 70 years), during the recruitment of HIV- PA60.

This will be a mixed study combining:

  • A "clinical" component comprising a stratified, comparative, international, multicenter cross-sectional study;
  • A "health systems strengthening" component combining a quantitative cross-sectional survey and a qualitative survey;
  • A qualitative socio-anthropological component including individual interviews and focus groups with people living with HIV60, their families and caregivers.

The 3 components will be conducted with a time lag between the different components due to the overlapping constitution of the source populations.

Most research on aging with HIV in the context of SSA has been very clinically focused (e.g., frailty or cognitive impairment). This research will provide a more comprehensive approach that takes into account the different levels of factors influencing health (individual, health system, social environment).

Read the detailed description

Methodology:

This is a mixed study combining:

  • a "clinical" component comprising a comparative, international, multicenter, two-strata (HIV+ and HIV-) cross-sectional study;
  • a "social sciences" component combining a quantitative cross-sectional survey and a qualitative survey involving individual interviews and focus groups with PA60, their families and caregivers.

Interventions:

  • Screening for several comorbidities (high blood pressure, diabetes, dyslipidemia, kidney failure, undernutrition, depression).
  • Comprehensive management including prevention strategies adapted to the various comorbidities mentioned above and their complications.

Statistical method:

Use of mixed approaches. For quantitative indicators, descriptive analysis techniques, bivariate analysis (Student t test or Wilcoxon test for quantitative variables, Chi² or Fisher test for categorical variables) and multivariate analysis (logistic regression).

02

Conditions studied

  • Older Adults

Browse trials for

Keywords

  • HIV
  • Frailty
  • Geriatric syndromes
  • Care pathways
03

In context

Frailty

1,291 studies on the registry are indexed under Frailty; 454 are open to participants now.

This study's planned enrollment of 600 is above the median of 225 across 495 observational studies indexed under Frailty.

Browse Frailty studies →

Lead sponsor

ANRS, Emerging Infectious Diseases is the lead sponsor of 215 studies on the registry; 38 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Clinical component

The targets of this component of the study are two specific populations:

  • People over the age of 60 (PA60) infected with HIV who are receiving treatment at HIV care centers in Abidjan (Ivory Coast), Bobo-Dioulasso (Burkina Faso), and Lomé (Togo), or who have recently been infected with HIV;
  • People over the age of 60 who are not infected with HIV.

Social science component:

  • PA60 HIV+/HIV-
  • Caregivers
  • Healthcare providers

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • + Group

    • Person 60 years of age and older
    • Infected with HIV-1 and/or 2
    • Able to move around the data collection site
    • Having given free and
  • HIV- Group

    • Person 60 years of age and older
    • HIV-uninfected
    • Able to move around the data collection site
    • Having given free and informed consent

Exclusion criteria

Exclusion Criteria:

Person deprived of liberty (guardianship, curatorship, judicial safeguard) Index 50≤50% Hospitalized

-

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
600 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • HIV positive group

    Individuals aged 60 years and over living with HIV-1 and/or HIV-2 attending HIV care centers in Abidjan, Bobo-Dioulasso and Lomé.

  • HIV negative group

    Individuals aged 60 years and over without HIV, matched by sex and age group.

06

What researchers measure

Primary outcomes

  1. Prevalence of frailty by HIV status among people aged 60 years and older (PA60) in West Africa

    Time frame: At 12 months

Secondary outcomes

  1. Prevalence of frailty in AP60

    Time frame: At 12 months

  2. Number and proportion of AP60 with geriatric syndrome

    Including cognitive, visual and hearing disorders, depression, undernutrition, dehydration, pain, urinary and fecal continence disorders, gait and balance disorders, according to HIV status

    Time frame: At 12 months

  3. Number and proportion of AP60 with at least one comorbidity

    Including cancer, dyslipidemia, diabetes, hypertension, history of myocardial infarction or stroke, osteoarticular disease, renal failure, according to HIV status

    Time frame: At 12 months

  4. Factors associated with the presence of geriatric syndromes

    Time frame: At t12 months

07

Study locations

1 of 6 sites recruiting
  • Hôpital de jour du CHU Sourou Sanou
    Bobo-Dioulasso, Burkina Faso
    Not yet recruiting
  • Centre Médical de Suivi des donneurs de sang (CMSDS)
    Treichville, Abidjan Autonomous District, Côte d’Ivoire
    Not yet recruiting
  • Service des Maladies Infectieuses et Tropicales (SMIT)
    Treichville, Abidjan Autonomous District, Côte d’Ivoire
    Not yet recruiting
  • Centre de Prise en Charge de Formation et de Recherche (CEPREF)
    Yopougon, Abidjan Autonomous District, Côte d’Ivoire
    Recruiting
  • ONG Espoir Vie Togo
    Lomé, Togo
    Not yet recruiting
  • Service des Maladies Infectieuses et Tropicales-CHU Sylvanus Olympio
    Lomé, Togo
    Not yet recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Sep 2026 (actual). Primary completion is estimated for Sep 2029, 36 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: start Mar 2026 → Sep 2026, primary completion Mar 2026 → Sep 2029 and completion Mar 2029 → Sep 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2026
First posted
Jan 21, 2026
StartActual
Sep 28, 2026was Mar 2026
Primary completionEst.
Sep 2029was Mar 2026
CompletionEst.
Sep 28, 2029was Mar 2029
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 2, 2026
Sites
6 sites changed recruiting status (5 now not yet recruiting, 1 now recruiting)
Show 6 sites
  • Hôpital de jour du CHU Sourou Sanou · Bobo-Dioulasso, Burkina Fasono status→Not yet recruiting
  • Centre Médical de Suivi des donneurs de sang (CMSDS) · Treichville, Côte d’Ivoireno status→Not yet recruiting
  • Service des Maladies Infectieuses et Tropicales (SMIT) · Treichville, Côte d’Ivoireno status→Not yet recruiting
  • Centre de Prise en Charge de Formation et de Recherche (CEPREF) · Yopougon, Côte d’Ivoireno status→Recruiting
  • ONG Espoir Vie Togo · Lomé, Togono status→Not yet recruiting
  • Service des Maladies Infectieuses et Tropicales-CHU Sylvanus Olympio · Lomé, Togono status→Not yet recruiting
Oct 2, 2026
Start date
Mar 2026→Sep 28, 2026 (actual)
Oct 2, 2026
Primary completion
Mar 2026→Sep 2029
Oct 2, 2026
Study completion
Mar 2029→Sep 28, 2029
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Not yet recruiting→Recruiting
    6 sites changed recruiting status (5 now not yet recruiting, 1 now recruiting)
    Show 6 sites
    • Hôpital de jour du CHU Sourou Sanou · Bobo-Dioulasso, Burkina Fasono status→Not yet recruiting
    • Centre Médical de Suivi des donneurs de sang (CMSDS) · Treichville, Côte d’Ivoireno status→Not yet recruiting
    • Service des Maladies Infectieuses et Tropicales (SMIT) · Treichville, Côte d’Ivoireno status→Not yet recruiting
    • Centre de Prise en Charge de Formation et de Recherche (CEPREF) · Yopougon, Côte d’Ivoireno status→Recruiting
    • ONG Espoir Vie Togo · Lomé, Togono status→Not yet recruiting
    • Service des Maladies Infectieuses et Tropicales-CHU Sylvanus Olympio · Lomé, Togono status→Not yet recruiting
    Start date Mar 2026→Sep 28, 2026 (now actual)
    Primary completion Mar 2026→Sep 2029
    Study completion Mar 2029→Sep 28, 2029
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07355413
Responsible party
Sponsor
First posted
Jan 21, 2026
Start date
Sep 28, 2026
Primary completion
Sep 2029 (estimated)
Completion
Sep 28, 2029 (estimated)
Last update
Oct 2, 2026

Study contacts

Fifonsi GBEASOR-KOMLANVI
Contact
fifonsi.gbeasor@gmail.com
+228 93 87 41 55
Clotilde ALLAVENA
principal investigator · Nantes University Hospital
Raoul MOH
principal investigator · Programme PAC-CI CHU de Treichville

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion